Her2 Neg Low Metastatic Breast Cancer clinical trials

Explore recruiting her2 neg low metastatic breast cancer clinical trials.

Also recruiting in Europe

Her2 Neg Low Metastatic Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

AIPAC-003: A randomized, double-blind, placebo-controlled Phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization

Spain, Belgium

Phase II and Phase III (Integrated) EU CTIS Study details

Her2 Neg Low Metastatic Breast Cancer trials by city

Her2 Neg Low Metastatic Breast Cancer in Toronto Her2 Neg Low Metastatic Breast Cancer in Vancouver Her2 Neg Low Metastatic Breast Cancer in Montreal Her2 Neg Low Metastatic Breast Cancer in Calgary Her2 Neg Low Metastatic Breast Cancer in Edmonton Her2 Neg Low Metastatic Breast Cancer in Ottawa Her2 Neg Low Metastatic Breast Cancer in Winnipeg Her2 Neg Low Metastatic Breast Cancer in Quebec City Her2 Neg Low Metastatic Breast Cancer in Hamilton Her2 Neg Low Metastatic Breast Cancer in Kitchener Her2 Neg Low Metastatic Breast Cancer in London Her2 Neg Low Metastatic Breast Cancer in Halifax Her2 Neg Low Metastatic Breast Cancer in New York Her2 Neg Low Metastatic Breast Cancer in Los Angeles Her2 Neg Low Metastatic Breast Cancer in Chicago Her2 Neg Low Metastatic Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease